Author: Gonzalo Alvaro

CLICK HERE to see the results video

We highlight in this half of 2024:

In this half-year, special attention should be drawn to the 2.8 percentage point increase in the gross margin when compared with the first half of 2023, rising to 59.4%.

Operating revenue decreased 14%, mainly due to a lower contribution from the CDMO business, sales of which decreased to 118.9 million euros.

Operating revenue generated by the specialty pharmaceutical business increased 1% to 210.5 million euros.

Sales of the heparin division (low-molecular-weight heparins and other heparins) totalled 120.7 million euros in the first half of the year.

Low-molecular-weight heparins decreased 2% to 116.9 million euros in the first half of 2024, mainly due to the drop in enoxaparin sales. However, a greater concentration of orders from partners is expected in the second half of 2024.

Bemiparin sales increased 6%, driven mainly by a higher volume of orders from partners in China, Turkey and Greece.

ROVI expects bemiparin sales to increase by a low-single-digit percentage in 2024 compared with 2023. Risperidone ISM® sales rose 141% in the first half of 2024 versus the same period of 2023, totalling 12.5 million euros.

In 2024, this product has been approved in the United States, Canada and Australia, thus reinforcing ROVI’s internationalisation strategy. Risperidone ISM® is expected to reach potential sales of between 200 and 300 million euros globally in upcoming years. R&D expenses rose 13% to 12.2 million euros. Regarding guidance for 2024, ROVI expects its operating revenue to decrease by a mid-single-digit percentage, although this guidance considers certain factors that could affect the estimates but are difficult to specify at present.

We’ll be waiting for you

Get ready for the change

The Investment Accelerator of the Community of Madrid has declared as a strategic project the expansion that Laboratorios ROVI will undertake at its plant in San Sebastián de los Reyes (Madrid), with which it plans to increase its current production capacity, thanks to the commissioning of a new high-speed line with a capacity of 100 million syringes.

The expansion project will involve an investment of around 60 million euros. The group has acquired adjoining land for a total area of 54,715 m2, which will increase production capacity by more than 31.5 percent to a total of 420 million prefilled syringes and 80 million vials by 2027.

To respond to the increase in activity, the group will incorporate new buildings for the expansion of production areas and new lines, a new quality laboratory and office building, and auxiliary storage and maintenance buildings, among others. The project envisages providing the industrial complex with new accesses and improving internal circulation, as well as increasing the number of parking spaces to meet the needs of the current and future workforce.

The various investments to increase the plant’s production capacity between 2023 and 2027 will create 200 new direct skilled jobs.

With this, the ROVI Group is positioned as one of the largest industrial pharmaceutical groups in Spain and among the world leaders in the production of injectables.

We are pleased to inform you that you have at your disposal the new version of the ROVI Group’s Environmental and Social Sustainability Policy, approved on 24 June 2024.

This document sets out the basic principles of the company’s sustainable behaviour in relation to its stakeholders.

As well as attached in this e-mail, you will find the policy on ROVI’s web site.

Clean-up team…Let’s go! The ROVI Team put on its gloves to clean up the Casa de Campo of rubbish on Saturday 15 July. Together with the Fundación Deporte y Desafío, the 15 ROVI volunteers organised themselves into teams to sweep the reclaimed area of the Manzanares River, starting at the fountain and the viewpoint of the Huerta de La Partida and continuing on to the Palacio de los Vargas.

But it wasn’t all about cleaning up, as we took the opportunity to learn a little more about the history behind both locations, while doing recycling workshops with members of the foundation. Mission accomplished!

We would like to share with you the video of the activity and encourage you to take part in the ROVI Team’s volunteering activities.

Do you have an efficient way to recycle that you would like to share with your colleagues? Any tips on how to use less electricity? Do you do any environmentally friendly activities? Submit it to THE GREEN IDEAS and enter the competition.

The competition entries will be presented to ROVI employees so that they can choose their favourite. The 3 most voted will be awarded with:

1st Prize: Gift Card 300€.
2nd Prize: Gift Card 150€.
3rd Prize: Gift Card 50€.

To enter the competition, please send an email to galvaros@rovi.es with:

• The subject of the email: NAME + GREEN IDEAS.
• Indicate your full name and contact number.
• Explain what it consists of. Send us a video telling or showing your idea. Remember to sign the Image Rights Authorisation in order to be able to share your proposal.

Deadline: 25 June

The ROVI Granada Team armed themselves with helmets and bicycles to tackle last Saturday’s bike ride with the Fundación Deporte y Desafío. During the 16-kilometre ride, the 15 ROVI volunteers were able to accompany the members of the foundation on their way to the adventure, completing the La Laguna route while enjoying the good weather and the views that accompanied them.

The starting point of the route was the Aura de la Naturaleza El Aguadero, where the volunteers were able to take the bikes provided by the foundation and set off. From there, a circular route awaited them, passing by the Ermita de la Virgen de la Cabeza (Cozvijar, Granada) and then continuing on to the Cascada del Río Dúrcal. A route with a low gradient and accessible to all participants.

Say goodbye to Diverclick. The new ROVI Discounts platform will bring more and better offers for ROVI employees.

If you are registered on the old Diverclick platform, you will have received an email where you can register on the new one. If you have accumulated money, don’t worry, as it will remain open for a while so you can spend it.

REGISTER FOR ROVI DISCOUNTS

Enter the platform by CLICKING HERE

• Go to “Create an account”. Complete the data by entering your corporate email address. If you don’t have one, enter a normal email address and enter the code: ROVI01.
• You will receive an email to complete your registration. It may take some time to arrive, depending on the registration traffic.

Take advantage of exclusive offers for ROVI employees. On the website you’ll find discounts in restaurants, supermarkets, cinemas, travel agencies, hotels, fashion, perfumery, homeware… and much more.

Effort, healthy competition and lots of laughter came together on 27 and 28 April at the ROVI Padel Tournament. A total of 42 pairs competed to see who was the best on the courts, dividing the participants into 3 categories according to their level: beginners, intermediate and advanced.

The championship took place at Club Fuencarral A La Par, where 12 padel courts were reserved to make the different phases of the tournament more dynamic. The competition started with a group stage on Saturday 27th, where only the best 4 pairs of each one would go through. On Sunday 28th the final tournament took place, where each pair fought to win their category.

WINNERS OF THE ROVI PADEL TOURNAMENT

Laboratorios Farmacéuticos ROVI announces the financial results obtained in the first quarter of 2024, that is critically important in establishing the bases for ROVI’s future growth.

The company closed the first quarter of 2024 with operating revenue of 151.2 million euros, EBITDA of 25.9 million euros and a net profit of 15.0 million.

Revenue from the CDMO business decreased 48% to 50.1 million, mainly due to lower revenue from manufacture of the COVID-19 vaccine in comparison with the first quarter of 2023, when ROVI booked higher revenue from production of the ”pandemic” vaccine and lower revenue related to the activities to prepare the plant for production of the vaccine under the agreement with Moderna.

Sales of the heparin franchise (low-molecular-weight heparins and other heparins) fell 8% to 56.3 million euros in the first quarter of 2024, due to a lower volume of orders from partners, since they held a higher level of stocks of these products from the fourth quarter of 2023. Sales of Risperidone ISM® evolved positively upwards to 5.4 million euros in the first quarter of the year, multiplying the 2023 first quarter figure by 2.4. In March 2024, ROVI received FDA approval for the marketing of Risperidone ISM® in the United States to treat schizophrenia in adults.

This is a historic milestone for the company as this is the first of its own product to receive marketing authorisation in the United States, the most important market worldwide for long-acting injectable antipsychotics.

Additionally, in the first quarter of 2024, ROVI approved marketing authorisation for this product in Canada and Australia. Research and development expenses rose 17% to 6.1 million euros and were mainly related to the development of phase 1 of Letrozole LEBE and the development of phase 1 of the new formulation of Risperidone ISM® for a three-monthly injection. Additionally, we were able to decrease operating expenses, excluding R&D and employee benefit expenses, by 11% as the result of an efficient cost containment policy.

Regarding guidance for 2024, ROVI expects its operating revenue to decrease by a mid-single-digit percentage, although this guidance considers certain factors that could affect the estimates but are difficult to specify at the present time. ROVI is in a new phase of growth and has confidence in the development potential of its specialty pharmaceuticals division and its CDMO business.